Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Assets (2016 - 2025)

Seres Therapeutics' Other Non-Current Assets history spans 10 years, with the latest figure at $31000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 93.33% year-over-year to $31000.0; the TTM value through Sep 2025 reached $31000.0, down 93.33%, while the annual FY2024 figure was $8.7 million, 296.34% up from the prior year.
  • Other Non-Current Assets for Q3 2025 was $31000.0 at Seres Therapeutics, down from $8.7 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $41.5 million in Q1 2024 and bottomed at $31000.0 in Q3 2025.
  • The 5-year median for Other Non-Current Assets is $8.2 million (2022), against an average of $7.6 million.
  • The largest annual shift saw Other Non-Current Assets surged 1479.57% in 2022 before it crashed 94.32% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $8.0 million in 2021, then increased by 2.31% to $8.2 million in 2022, then plummeted by 73.28% to $2.2 million in 2023, then soared by 296.34% to $8.7 million in 2024, then plummeted by 99.64% to $31000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Other Non-Current Assets are $31000.0 (Q3 2025), $8.7 million (Q2 2025), and $8.7 million (Q1 2025).